{"id":959124,"date":"2026-05-06T16:30:42","date_gmt":"2026-05-06T20:30:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/orasure-announces-first-quarter-2026-financial-results\/"},"modified":"2026-05-06T16:30:42","modified_gmt":"2026-05-06T20:30:42","slug":"orasure-announces-first-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orasure-announces-first-quarter-2026-financial-results\/","title":{"rendered":"OraSure Announces First Quarter 2026 Financial Results"},"content":{"rendered":"
\n

BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.<\/p>\n

\u201cOur Q1 results were consistent with our expectations, and revenue of $27.9 million was above the midpoint of our guidance range,\u201d said Carrie Eglinton Manner, President and CEO of OTI. \u201cWe delivered gross margin expansion in Q1 and remain focused on leveraging our manufacturing capabilities and capacity to drive additional operating efficiencies.\u201d<\/p>\n

She continued, \u201cOraSure is well positioned to accelerate our growth as we approach a series of regulatory and commercial milestones in 2026 and continue to transform our business through our strategy to decentralize diagnostics and connect people to care that is more accessible, convenient, affordable, and private. Additionally, our strong balance sheet gives us the flexibility to pursue acquisitions and partnerships that strengthen our portfolio, while continuing to invest in R&D aimed at high\u2011value growth markets in order to drive long\u2011term value for shareholders.\u201d<\/p>\n

\n Financial Highlights ($ in 000\u2019s, except per share amounts)<\/strong>\n <\/p>\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\n For the Three Months Ended March 31,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>
\n
\n
\n <\/strong>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>
\n
\n
\n <\/strong>\n <\/td>\n		\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
Core Business (1)<\/sup><\/td>\n$<\/td>\n27,907<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n28,050<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(1<\/td>\n)%<\/td>\n<\/tr>\n
COVID-19<\/td>\n\u00a0<\/td>\n18<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n461<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(96<\/td>\n)<\/td>\n<\/tr>\n
Risk Assessment Testing<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,420<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(100<\/td>\n)<\/td>\n<\/tr>\n
\n Total Net Revenues<\/strong>\n <\/td>\n$<\/td>\n27,925<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n29,931<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(7<\/td>\n)%<\/td>\n<\/tr>\n<\/table>\n

\n (1)<\/sup> Includes Diagnostics, Sample Management Solutions, other products and services revenues, and non-product and services revenues.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n For the Three Months Ended March 31,<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Net revenues<\/td>\n\u00a0<\/td>\n27,925<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n29,931<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(7<\/td>\n)%<\/td>\n<\/tr>\n
Gross profit<\/td>\n\u00a0<\/td>\n11,804<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n12,299<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(4<\/td>\n) <\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n42.3<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n41.1<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP gross profit<\/td>\n\u00a0<\/td>\n12,107<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n12,468<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(3<\/td>\n) <\/td>\n<\/tr>\n
Non-GAAP gross margin<\/td>\n\u00a0<\/td>\n43.4<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n41.7<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating loss<\/td>\n\u00a0<\/td>\n(23,269<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(17,750<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating margin<\/td>\n(83.3<\/td>\n)%<\/td>\n\u00a0<\/td>\n(59.3<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP operating loss<\/td>\n\u00a0<\/td>\n(19,034<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(15,280<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP operating margin<\/td>\n(68.2<\/td>\n)%<\/td>\n\u00a0<\/td>\n(51.1<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net loss<\/td>\n\u00a0<\/td>\n(22,377<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(16,040<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP net (loss) income<\/td>\n\u00a0<\/td>\n(17,022<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(13,139<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Diluted GAAP EPS<\/td>\n$<\/td>\n(0.32<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.21<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n
Diluted Non-GAAP EPS<\/td>\n$<\/td>\n(0.24<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.18<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

NM \u2013 not meaningful<\/p>\n